Do insulin resistance and hyperglycemia drive an atherogenic lipid profile and vascular inflammation?

Insulin resistance and hyperglycemia are foundational drivers of a specific atherogenic lipid profile characterized by increased triglyceride-rich lipoproteins (TRLs) and small dense LDL (sdLDL). This metabolic state initiates a cascade of lipoprotein remodeling and oxidative modification that significantly elevates cardiovascular risk.

Lipoprotein remodeling and ApoB burden

Under normal conditions, insulin suppresses hepatic VLDL secretion. In insulin-resistant states, this suppression fails. Hyperglycemia activates transcription factors such as SREBP-1c and ChREBP, which upregulate hepatic de novo lipogenesis, providing substrates for excessive VLDL1 assembly.

• ApoB dynamics: Because every VLDL, IDL, and LDL particle contains a single molecule of Apolipoprotein B-100 (ApoB), the overproduction of TRLs and their subsequent remodeling into sdLDL directly increases the total ApoB particle burden.
• Formation of sdLDL: Large, triglyceride-rich VLDL1 particles undergo lipid exchange via cholesteryl ester transfer protein (CETP). Hepatic lipase (HL) then hydrolyzes these particles, shrinking them into small, dense LDL subfractions.

Oxidative susceptibility and inflammation

The physical properties of sdLDL and TRL remnants render them highly susceptible to chemical modification.

• Oxidative mechanisms: The reduced diameter of sdLDL limits its capacity to carry antioxidants like vitamin E. Furthermore, structural shifts in the ApoB-100 protein (from alpha-helical to beta-strand) expose domains to lipid peroxidation, shortening the oxidation lag time.
• Vascular inflammatory cascade: Oxidized LDL (oxLDL) binds to LOX-1 receptors on endothelial cells and macrophages, triggering the NF-κB transcription factor pathway. This activation upregulates pro-inflammatory cytokines (IL-6, TNF-α) and adhesion molecules (VCAM-1, ICAM-1), facilitating monocyte recruitment.
• Clinical markers: This process is reflected in elevated biomarkers such as high-sensitivity C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2), which indicate active plaque inflammation and instability.

Bottom line

Insulin resistance and hyperglycemia drive the production of TRLs and sdLDL, which increases total ApoB particle count. These particles are uniquely prone to oxidation, leading to LOX-1/NF-κB activation and chronic vascular inflammation, even when standard LDL cholesterol levels appear normal.